Management of Deranged Liver Function Tests in Patients on Anti-Tubercular Therapy

Introduction to Management

The American College of Radiology suggests grading the severity of hepatotoxicity, with mild being ALT/AST <5× ULN, moderate being 5-10× ULN, and severe being >10× ULN 2
The management of deranged liver function tests (LFTs) in patients on anti-tubercular therapy involves immediately discontinuing the offending agent if liver enzymes are elevated >3-5× ULN or if any elevation occurs with symptoms or jaundice, then systematically investigating for alternative causes while monitoring closely for improvement, as recommended by Praxis Medical Insights 1

The severity of hepatotoxicity should be graded, and the pattern of liver injury determined, with hepatocellular injury showing predominant transaminase elevation, cholestatic injury showing alkaline phosphatase elevation, and mixed patterns presenting both, according to the Journal of the American College of Radiology 2
Monitoring frequency should be twice weekly if on potentially hepatotoxic medications, and more frequently if abnormal liver function persists, as suggested by The Lancet Gastroenterology and Hepatology 4
Expected timeline for improvement is within 8-12 weeks after discontinuation of the offending agent, and if LFTs fail to normalize, investigation for other chronic liver diseases should be considered, as recommended by The Lancet Gastroenterology and Hepatology 4

Standard investigations for liver diseases should be performed, including viral hepatitis serology, metabolic workup, autoimmune markers, and imaging of the liver and biliary tract, as recommended by The Lancet Gastroenterology and Hepatology and Praxis Medical Insights 1, 4
Review of alcohol history and other hepatotoxic medications is also essential, as suggested by The Lancet Gastroenterology and Hepatology 4

Once LFTs improve to Grade 1 or normalize, consideration should be given to reintroducing anti-tubercular therapy with a modified regimen, using less hepatotoxic alternatives when possible, as recommended by Praxis Medical Insights 1
Monitoring of LFTs should be more frequent (every 2-4 weeks) for at least 3 months after restarting therapy, as suggested by Praxis Medical Insights 1

Supportive measures should include ensuring adequate caloric intake, avoiding prolonged fasting, monitoring for and correcting hypoglycemia and electrolyte abnormalities, as recommended by Praxis Medical Insights 1
HBV reactivation risk should be considered, and antiviral prophylaxis initiated if necessary, as recommended by The Lancet Gastroenterology and Hepatology 7
Urgent referral should be considered in cases of signs of acute liver failure, progressive deterioration despite medication discontinuation, or severe elevation with bilirubin >2× ULN, as suggested by Praxis Medical Insights and The Lancet Gastroenterology and Hepatology 1, 7